GUIDELINES & RESOURCES

COVID-19: Pfizer-BioNTech Vaccines for Children as Young as 6 Months — New Codes

On June 17, 2022, the FDA amended the Pfizer-BioNTech COVID-19 vaccine emergency use authorization (PDF) to authorize use for all patients 6 months – 4 years old. Get important vial and dosing information. CMS issued new CPT codes effective June 17, 2022:

Code 91308 for vaccine product:

• Long descriptor: Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNALNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use
• Short descriptor: SARSCOV2 VAC 3 MCG TRS-SUCR

Code 0081A for vaccine administration, first dose:

• Long descriptor: Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNALNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose
• Short descriptor: ADM SARSCV2 3MCG TRS-SUCR 1

Code: 0082A for vaccine administration, second dose:

• Long descriptor: Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNALNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose
• Short descriptor: ADM SARSCV2 3MCG TRS-SUCR 2

Code 0083A for vaccine administration, third dose:

• Long descriptor: Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNALNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; third dose
• Short descriptor: ADM SARSCV2 3MCG TRS-SUCR 3

Visit the COVID-19 Vaccine Provider Toolkit for more information, and get the most current list of billing codes, payment allowances, and effective dates. Note: you may need to refresh your browser if you recently visited this webpage.

The FDA released a new checklist to help clinicians determine which patients are eligible for Paxlovid, an oral antiviral for mild to moderate COVID-19 in adults and some pediatric patients who are at high risk for severe COVID-19. The agency also updated a Paxlovid fact sheet with more specific recommendations. Learn more.

CDC updates COVID-19 Testing:

What You Need to Know (updated 12/29) with videos/posters to share with patients and families.

COVID-19 Monoclonal Antibody EUA Updates: casirivimab/imdevimab

CMS posted technical updates to the Monoclonal Antibody COVID-19 Infusion and COVID-19 Vaccines and Monoclonal Antibodies webpages to reflect updates to the Emergency Use Authorization (EUA) for casirivimab and imdevimab, a COVID-19 monoclonal antibody. 

COVID-19 Vaccine Patient Education | Resources to help answer your patients' questions

Customize and use any of the Encouraging COVID-19 Vaccinations: Sample Patient Education Messages in your patient portal, newsletters or emails.

Use the Debunking Common COVID-19 Vaccine Myths article on familydoctor.org to correct misconceptions your patients might have, like: 

• The COVID-19 vaccines were developed too fast to be safe.
• There weren't enough participants in clinical trials to declare the vaccines safe.
• I won't need to wear a mask after I am vaccinated.

COVID 19 general and vaccination resource pages
Wisconsin COVID information for providers

New Resource for COVID-19: CDC/IDSA Real-Time Learning Network

The American Academy of Family Physicians has been selected by the CDC as a collaborator in the COVID-19 Real-Time Learning Network (RTLN). The RTLN is a collaborative effort led by the Infectious Diseases Society of America to provide access to the latest information on fighting COVID-19 by bringing together the many health care disciplines fighting this pandemic to share resources and best practices, and ultimately decrease the impact of COVID-19 and save lives.  The goal of the network is to bring value, support, and guidance to healthcare providers treating COVID-19 patients through education, communication and outreach.  Read More

If your clinic, pharmacy, or health care system plans to administer Covid vaccines, please see the message below from the Immunization Program of the Wisconsin Department of Health Services.

The state is asking vaccinators to register for the Wisconsin COVID-19 Vaccine program.  Clinics, pharmacies, or health care systems should register for the program as soon as possible before vaccine is available.  Vaccinators that plan to vaccinate populations such as health care workers, essential workers, or people 65+ years are high priority for the state.  Covid vaccine will NOT be available for private purchase; it will only be available for through the state’s Covid vaccine program.By enrolling in the COVID-19 Vaccine program, vaccinators will be approved to administer COVID-19 vaccine in Wisconsin once a safe and effective vaccine is made available. COVID-19 vaccine will not be available for private purchase; it will only be available for delivery through the Wisconsin COVID-19 Vaccine program.

Which vaccinating entities should enroll?
Enrollment is open to all providers that will vaccinate against COVID-19 such as: health care systems; health care providers; pharmacies; local and tribal health departments; mass vaccination sites; and long term care facilities (LTC) and assisted living facilities (ALF) that are not participating in the Pharmacy Partnership program.

If your organization plans to administer COVID-19 vaccine, please register as soon as possible, especially if you plan to vaccinate priority populations such as health care workers, essential workers, or people 65+ years.

How to enroll?
Please follow the steps outlined on our COVID-19 Vaccinator page.

When will my entity receive COVID-19 vaccine?
After completing enrollment and obtaining approval from the Wisconsin COVID-19 Vaccine program, your entity will receive COVID-19 vaccine as supply allows. During the first phases of vaccination, it is anticipated that the Wisconsin COVID-19 Vaccine program will be allocated a limited supply of COVID-19 vaccine and therefore, recommendations will be limited to certain priority groups. The program plans to focus shipments of vaccine to entities that can vaccinate those early priority groups.

Over time, as vaccine supply increases, we anticipate vaccine allocations and recommendations will expand to other groups.